Neurofibromatosis type I

For Von Recklinghausen's disease of bone, a disorder seen with hyperparathyroidism, see osteitis fibrosa cystica.

Neurofibromatosis type 1
Other names	von Recklinghausen disease morbus Recklinghausen NF1
Main symptoms of neurofibromatosis type I. [1]
Specialty	Neurosurgery, dermatology, ophthalmology
Usual onset	At birth

Neurofibromatosis type I (NF-1), or von Recklinghausen syndrome, is a complex multi-system human disorder caused by the mutation of neurofibromin 1 (NF-1). NF-1 is a gene on chromosome 17 that is responsible for production of a protein (neurofibromin) which is needed for normal function in many human cell types. NF-1 causes tumors along the nervous system that can grow anywhere on the body. NF-1 is one of the most common genetic disorders and is not limited to any person's race or sex. NF-1 is an autosomal dominant disorder, which means that mutation or deletion of one copy (or allele) of the NF-1 gene is sufficient for the development of NF-1, although presentation varies widely and is often different even between relatives affected by NF-1. ^[2]

As of 2015 ^[update] , there are at least 100,000 people in the U.S. and about 25,000 people in the UK who have been diagnosed with NF. Common symptoms of NF-1 include brownish-red spots in the colored part of the eye called Lisch nodules, benign skin tumors called neurofibromas, and larger benign tumors of nerves called plexiform neurofibromas, scoliosis (curvature of the spine), learning disabilities, vision disorders, mental disabilities, multiple café au lait spots and epilepsy. While some people have major complications, others with the condition can lead productive and full lives.

NF-1 is a developmental syndrome caused by germline mutations in neurofibromin, a gene that is involved in the RAS pathway (RASopathy). Due to its rarity, and to the fact that genetic diagnosis has been used only in recent years, in the past NF-1 was in some cases confused with Legius syndrome, another syndrome with vaguely similar symptoms, including cafe-au-lait spots. ^[3]

NF-1 is an age-specific disease; most signs of NF-1 are visible after birth (during infancy), but many symptoms of NF-1 occur as the person ages and has hormonal changes. NF-1 was formerly known as von Recklinghausen disease, after the researcher who first documented the disorder, Friedrich Daniel von Recklinghausen. ^[4]

The severity of NF-1 varies widely, and little is known about what causes a person to have more severe or less severe symptoms. Even within the same family (as there is a 50% chance that a parent will pass their condition to their offspring), levels of severity can vary enormously. ^[2] 60% of people with NF-1 have mild cases, with few symptoms that have very little effect in their day-to-day lives. About 20% of people with NF-1 have what are considered moderate cases, with several symptoms that usually have a few cosmetic effects. The other 20% have severe cases, with several symptoms that affect the person's quality of life. Even in this last group, symptoms are rarely life-threatening. ^[5]

Signs and symptoms

Café au lait spot characteristic of NF1

Diagnostic criteria of neurofibromatosis type I, requiring at least 2 of the mentioned items.

The following is a list of conditions and complications associated with NF-1, and, where available, age range of onset and progressive development, occurrence percentage of NF-1 population, method of earliest diagnosis, and treatments and related medical specialties. ^{[7] [8]} The progression of the condition is roughly as follows:

1. Congenital musculoskeletal disorders may or may not be present
2. Cutaneous conditions may be observed in early infancy
3. Small tumors may arise in the retina which can eventually lead to blindness. Also, Lisch Nodules may grow on the iris, but these are harmless.
4. Learning disabilities may arise in preschool children
5. Neurofibromas may occur and can sometimes cause many dependent neurological conditions and cutaneous and skeletal disfigurement.
6. Depression and social anxiety may occur as a result of disabilities caused by the condition
7. Neurofibromas may, in 8-13% of cases, transition into cancer, which can be fatal ^[9]

Musculoskeletal disorder

Musculoskeletal abnormalities affecting the skull include sphenoid bone dysplasia, congenital hydrocephalus and associated neurologic impairment.

Disorders affecting the spine include:

• In NF-1, there can be a generalized abnormality of the soft tissues in the fetus, which is referred to as mesodermal dysplasia, resulting in maldevelopment of skeletal structures.
• Meningoceles and formation of cystic diverticula of the dura of the spine, unrelated to Spina bifida
• Radiographically, dural ectasia can lead to scalloping of the posterior vertebral bodies and to the formation of cystic diverticula of the dura of the spine. This may result in temporary or permanent loss of lower extremity sensorimotor function. ^[10]
• Focal scoliosis and/or kyphosis are the most common skeletal manifestation of NF-1, occurring in 20% of affected patients. Approximately 25% of patients will require corrective surgery.

Skeletal muscle weakness and motor control deficits

Deficits in motor function in NF-1 have been long recognised and have been historically attributed to nerve dysfunction. In recent years however, studies suggest NF-1 is associated with a primary problem in muscle function (myopathy). ^[11]

Clinical findings in people with NF-1 include:

• Reduced skeletal muscle size
• Reduced exercise capacity
• Muscle weakness (The most recent study reports between 30–50% reduced upper and lower limb muscle strength in NF-1 children compare with matched controls ^[12] ).

Studies in genetically modified mice have thus far confirmed that the NF1 gene is vital for normal muscle development and metabolism. Knockout of the NF1 gene in muscle results in deregulated lipid metabolism and muscle weakness. ^{[11] [13]}

NF-1 is a disease in the RASopathy family of diseases, which include Costello Syndrome, Noonan Syndrome, and Cardiofaciocutaneous syndrome. The RASopathies also present with skeletal muscle weakness. ^[14] It is likely that impaired muscle function in these disorders is linked to altered Ras/MAPK signalling, however, the precise molecular mechanisms remain unknown. ^[11]

Facial bones and limbs

See also: List of radiographic findings associated with cutaneous conditions

• Bowing of a long bone with a tendency to fracture and not heal, yielding a pseudarthrosis. The most common bone to be affected is the tibia, causing congenital pseudarthrosis of the tibia or CPT. CPT occurs in 2–4% of individuals with NF-1. Treatment includes limb amputation or correction by Ilizarov method as a limb-sparing technique.
• Malformation of the facial bones or of the eye sockets (lambdoid suture defects, sphenoid dysplasia)
• Unilateral overgrowth of a limb. When a plexiform neurofibroma manifests on a leg or arm, it will cause extra blood circulation, and may thus accelerate the growth of the limb. This may cause considerable difference in length between left and right limbs. To equalize the difference during childhood, there is an orthopedic surgery called epiphysiodesis, where growth at the epiphyseal (growth) plate is halted. It can be performed on one side of the bone to help correct an angular deformity, or on both sides to stop growth of that bone completely. The surgery must also be carefully planned with regard to timing, as it is non-reversible. The goal is that the limbs are at near-equal length at end of growth.

Skin

See also: List of conditions associated with café au lait macules

• Flat pigmented lesions of the skin called café au lait spots, are hyper pigmented lesions that may vary in color from light brown to dark brown; this is reflected by the name of the condition, which means "coffee with milk". The borders may be smooth or irregular. These spots can grow from birth and can continue to grow throughout the person's lifetime. They can increase in size and numbers during puberty and during pregnancies. They are present in about 99% of patients of European origin and in about 93% of patients of Indian origin. ^[15]
• Freckling of the axillae or inguinal regions.
• Dermal neurofibroma, manifested as single or multiple firm, rubbery bumps of varying sizes on a person's skin. Age of onset is puberty. Progressive in number and size. Not malignant. Can be treated with CO₂ lasers or by removal by a plastic surgeon specialized in NF1. ^{[16] [17]}

Eye disease

• Lisch nodules in the iris.
• Optic nerve gliomas along one or both optic nerves or the optic chiasm can cause bulging of the eyes, involuntary eye movement, squinting, and / or vision loss. Treatment may include surgery, radiation +/- steroids, or chemotherapy (in children). ^[18]

Neurobehavioral developmental disorder

The most common complication in patients with NF-1 is cognitive and learning disability. These cognitive problems have been shown to be present in approximately 90% of children and adults with NF-1 and have significant effects on their schooling and everyday life. ^[19] These cognitive problems have been shown to be stable into adulthood mainly in the mid 20s to early 30s and do not get worse unlike some of the other physical symptoms of NF-1. ^[20] The most common cognitive problems are with perception, executive functioning and attention. Disorders include:

• Approximately 42% of children with NF-1 have symptoms of autism, with 36.78% of them being severe cases, 33.33% being mild to moderate cases, and 29.89% of them having both symptoms of autism and ADHD. ^[21]
• Attention deficit hyperactivity disorder has been shown to be present in approximately 40% of children with NF-1. ^[21]
• Speech and language delays have also been identified in approximately 68% of preschool children with NF-1. ^[22]
• Motor deficits are common. Motor deficits due to NF-1 are probably not cerebellar. ^[23]
• Spatial deficit.^{[ citation needed ]}

Nervous system disease

The primary neurologic involvement in NF-1 is of the peripheral nervous system, and secondarily of the central nervous system. Schwannomatosis is a rare condition defined by the presence of multiple benign tumors of nerves that are frequently very painful. In addition to pain, weakness is a common problem. Symptoms usually begin in young or mid-adult years.^{[ citation needed ]}

Peripheral neuropathy

Neurofibroma

A neurofibroma is a lesion of the peripheral nervous system. Its cellular lineage is uncertain, and may derive from Schwann cells, other perineural cell lines, or fibroblasts. Neurofibromas may arise sporadically, or in association with NF-1.

Neurofibroma conditions are progressive and include:

• Plexiform neurofibroma: Often congenital. Lesions are composed of sheets of neurofibromatous tissue that may infiltrate and encase major nerves, blood vessels, and other vital structures. These lesions are difficult and sometimes impossible to routinely resect without causing any significant damage to surrounding nerves and tissue.
• Solitary neurofibroma, affecting 8–12% of patients with NF-1. This occurs in a deep nerve trunk. Diagnosis by cross-sectional imaging (e.g., computed tomography or magnetic resonance) as a fusiform enlargement of a nerve.
• Schwannomas, peripheral nerve-sheath tumors which are seen with increased frequency in NF-1. The major distinction between a schwannoma and a solitary neurofibroma is that a schwannoma can be resected while sparing the underlying nerve, whereas resection of a neurofibroma requires the sacrifice of the underlying nerve.
• Nerve root neurofibroma.
• Bones, especially the ribs, can develop chronic erosions (pits) from the constant pressure of adjacent neurofibroma or schwannoma. Similarly, the neural foramen of the spine can be widened due to the presence of a nerve root neurofibroma or schwannoma. Surgery may be needed when NF-1 related tumors compress organs or other structures.

Nerve sheath tumor

MRI image showing malignant peripheral nerve sheath tumor in the left tibia in neurofibromatosis type-1

• Chronic pain, numbness, and/or paralysis due to peripheral nerve sheath tumor.^{[ citation needed ]}

Other complications

• Renal artery anomalies or pheochromocytoma and associated chronic hypertension
• Schwannoma
• Plexiform fibromas
• Optic nerve glioma
• Epilepsy

Central nervous system disease

Epilepsy

Main article: Epilepsy

• Occurrence. Epileptic seizures have been reported in up to 7% of NF-1 patients. ^[24]
• Diagnosis. Electroencephalograph, magnetic resonance imaging, computed tomographic scan, single-photon emission CT and positron emission tomographic scan.
• Etiology. Due to cerebral tumors, cortical malformation, mesial temporal sclerosis.
• Therapy. Drug therapy (57% amenable) where not resistant (29%).

Glial tumors

Main article: Glial tumor

Intracranially, NF-1 patients have a predisposition to develop glial tumors of the central nervous system, primarily optic nerve gliomas and associated blindness. ^[25]

Focally degenerative myelin

Another CNS manifestation of NF-1 is the so-called "unidentified bright object" or UBO, which is a lesion which has increased signal on a T2 weighted sequence of a magnetic resonance imaging examination of the brain. These UBOs are typically found in the Cerebral peduncle, pons, midbrain, globus pallidus, thalamus, and optic radiations. Their exact identity remains a bit of a mystery since they disappear over time (usually, by age 16), and they are not typically biopsied or resected. They may represent a focally degenerative bit of myelin.^{[ citation needed ]}

Dural ectasia

Main article: Dural ectasia

Within the CNS, NF-1 manifests as a weakness of the dura, which is the tough covering of the brain and spine. Weakness of the dura leads to focal enlargement due to chronic exposure to the pressures of CSF pulsation, and typically presents as paraesthesia or loss of motor or sensory function. ^[10] It has been shown that dural ectasia occur near plexiform neurofibromas which may be infiltrative leading to weakening of the dura. ^[26]

Acetazolamide has shown promise as a treatment for this condition, and in very few cases do dural ectasia require surgery. ^[26]

Mental Health

People with NF1 are at increased risk for experiencing social and emotional difficulties such as; anxiety, depression, low self-esteem and/or body image, social withdrawal, difficulty forming interpersonal relationships, behavioural problems, and difficulties in school. ^[27] People with NF1 are much more likely to experience suicidal thoughts than the general population. One study found that 45% of people with NF had suicidal thoughts compared to 10% of a healthy control group. ^[28] Another study found that 46.5% were of people with NF1 were found to have at least one psychiatric comorbid diagnosis. ^[29]

Neurodivergence

Children and adults with NF-1 often have Autism and/or ADHD.

• 30 - 50% of people with NF1 also meet the diagnostic criteria for ADHD ^[30]
• 11 - 26% of people with NF1 also have Autism Spectrum Disorder ^[31]

Puberty and height

Children diagnosed with NF-1 may experience delayed or precocious puberty. Recent studies have correlated precocious puberty in individuals with NF-1 with the presence of optic pathway tumours. ^[32] Furthermore, the heights of children affected by NF-1 have been shown to increase normally until puberty, after which increases in height lessen when compared to healthy counterparts. ^[32] This eventually causes a shorter stature than expected in individuals with NF-1.

Cancer

Cancer can arise in the form of malignant peripheral nerve sheath tumor resulting from malignant degeneration of a plexiform neurofibroma. ^{[33] [34]}

• Frequency. A plexiform neurofibroma has a lifetime risk of 8–12% of transformation into a malignant tumor.
• Diagnosis. MRI.
• Treatment. Surgery (primary), radiation therapy.
• Mortality. Malignant nerve sheath tumor was the main cause of death (60%) in a study of 1895 patients with NF-1 from France in the time period 1980–2006 indicated excess mortality in NF-1 patients compared to the general population. ^[35] The cause of death was available for 58 (86.6%) patients. The study found excess mortality occurred among patients aged 10 to 40 years. Significant excess mortality was found in both males and females.

Breast Cancer

Biological females with NF also have a five-fold increased risk of breast cancer and may have an increased breast cancer related mortality. The median survival for breast cancer in people with NF was 5 years vs. the reported median survival of over 20 years in the general population using the SEER database. ^{[36] [37]}

Cause

Main article: Neurofibromin 1

Neurofibromin 1 gene

NF-1 is a microdeletion syndrome caused by a mutation of a gene located on chromosomal segment 17q11.2 on the long arm of chromosome 17 which encodes a protein known as neurofibromin ^[38] (not to be confused with the disorder itself) which plays a role in cell signaling. ^{[39] [40]} The Neurofibromin 1 gene is a negative regulator of the Ras oncogene signal transduction pathway. It stimulates the GTPase activity of Ras.

In 1989, through linkage and cross over analyses, neurofibromin was localized to chromosome 17. ^[41] It was localized to the long arm of chromosome 17 by chance when researchers discovered chromosome exchanges between chromosome 17 with chromosome 1 and 22. ^[41] This exchange of genetic material presumably caused a mutation in the neurofibromin gene, leading to the NF1 phenotype. Two recurrent microdeletion types with microdeletion breakpoints located in paralogous regions flanking NF1 (proximal NF1-REP-a and distal NF1-REP-c for the 1.4 Mb type-1 microdeletion, and SUZ12 and SUZ12P for the 1.2 Mb type-2 microdeletion), are found in most cases. ^[42]

Structure

The neurofibromin gene was soon sequenced and found to be 350,000 base pairs in length. ^[43] However, the protein is 2818 amino acids long leading to the concept of splice variants. ^[44] For example, exon 9a, 23a and 48a are expressed in the neurons of the forebrain, muscle tissues and adult neurons respectively. ^[44]

Homology studies have shown that neurofibromin is 30% similar to proteins in the GTPase activating protein (GAP) family. ^[43] This homologous sequence is in the central portion of neurofibromin and being similar to the GAP family is recognized as a negative regulator of the Ras kinase. ^[45]

Additionally, being such a large protein, more active domains of the protein have been identified. One such domain interacts with the protein adenylyl cyclase, ^[46] and a second with collapsin response mediator protein. ^[47] Together, likely with domains yet to be discovered, neurofibromin regulates many of the pathways responsible for overactive cell proliferation, learning impairments, skeletal defects and plays a role in neuronal development. ^[48]

Inheritance and spontaneous mutation

NF-1 is inherited in an autosomal dominant fashion, although it can also arise due to spontaneous mutation.

The mutant gene is transmitted with an autosomal dominant pattern of inheritance, but up to 50% of NF-1 cases arise due to spontaneous mutation. The incidence of NF-1 is about 1 in 3500 live births. ^[49]

Diagnosis

Prenatal testing and prenatal expectations

Prenatal testing may be used to identify the existence of NF-1 in the fetus. For embryos produced via in vitro fertilisation, it is possible via preimplantation genetic diagnosis to screen for NF-1. ^[50]

While the presence of NF-1 can be identified through prenatal testing the severity with which the condition will be expressed is impossible to determine. ^[51]

People with NF-1 have a 50% percent chance of passing the disorder to their offspring, but people can have a child born with NF-1 when they themselves do not have the condition. This is caused by a spontaneous mutation.

Post-natal testing

The National Institutes of Health (NIH) has created specific criteria for the diagnosis of NF-1. Two of these seven "Cardinal Clinical Features" are required for positive diagnosis. ^{[52] [53]} There is practical flowchart to distinguish between NF1, NF2 and schwannomatosis. ^[54]

• Six or more café-au-lait spots over 5 mm in greatest diameter in pre-pubertal individuals and over 15 mm in greatest diameter in post-pubertal individuals. Note that multiple café-au-lait spots alone are not a definitive diagnosis of NF-1 as these spots can be caused by a number of other conditions.
• Two or more neurofibromas of any type or 1 plexiform neurofibroma
• Freckling in the axillary (Crowe sign) or inguinal regions
• Optic nerve glioma
• Two or more Lisch nodules (pigmented iris hamartomas)
• A distinctive osseous lesion such as sphenoid dysplasia, or thinning of the long bone cortex with or without pseudarthrosis.
• A first degree relative (parent, sibling, or offspring) with NF-1 by the above criteria.

Psychological and Neurodevelopmental Disorders

In addition to physical manifestations, patients with NF1 are at high risk of developing neurodevelopmental disorders, which result in learning difficulties, attention problems, and other behavioral or social challenges. ^[55] Studies have shown that children with NF1 are particularly prone to being affected by conditions such as Attention Deficit Hyperactivity Disorder (ADHD) or Autism Spectrum Disorder (ASD), as well as psychological disorders such as anxiety or depression, highlighting the importance of multidisciplinary evaluation and care for these patients. ^[55]

Autism spectrum disorder in NF-1

A significant number of children with NF-1 exhibit symptoms commonly associated with Autism Spectrum Disorder (ASD), which can impact daily functioning. ^[56] These symptoms may include difficulties with flexibility and transitions, repetitive behaviors, challenges in social communication, social awareness, and adaptability. ^[56]

Some studies have identified subtle but significant differences between ASD symptomatology in individuals with NF-1 and those with idiopathic autism. ^[57] These differences include stronger eye contact, fewer repetitive behaviors, and more pronounced autistic mannerisms compared to non-syndromic ASD. ^[58] Enhanced language skills have also been noted in this population. ^[57] More than 90% of children with ASD + NF1 demonstrate clinically significant challenges in interpreting social signals and social communication during interactions. ^[57]

Discrepancies have been noted between parent-report questionnaires, such as the Social Responsiveness Scale (SRS), and clinical observation tools as in the case of the Autism Diagnostic Observation Schedule (ADOS), suggesting that restricted repetitive behaviors in NF-1 autism may be qualitatively different or less severe than in idiopathic autism, and therefore may go undetected in ADOS assessments. ^[57]

Studies indicate that parent-reported scores on the autistic mannerisms subscale of the SRS questionnaire were notably high, with two-thirds of children with NF-1 + ASD scoring in the severe problem range. ^[57]

Regarding items assessing imagination and creativity, children with NF-1 + ASD exhibit similar levels of impairment as the autism group, while being significantly more affected than children with only ASD. ^[57] Furthermore, no differences were observed between the groups on items measuring hyperactivity. Similarly, no evidence of group differences was found for the anxiety item, which is also associated with certain genetic disorders, such as Fragile X syndrome and Cornelia de Lange syndrome. ^[57]

Research suggests that Neurofibromatosis Type 1 and Tuberous Sclerosis (TSC) exhibit similarities in the symptomatology associated with Autism Spectrum Disorder. ^[58] These findings may indicate the existence of shared neurobiological characteristics between the two syndromes that influence the presentation of ASD symptoms.

Due to their fewer observed repetitive behaviors and improved eye contact, these children may not exhibit the typical characteristics of idiopathic autism in clinical settings, increasing the likelihood that they will be overlooked by clinicians. ^[57]

Unlike idiopathic ASD, both males and females seem to be equally affected, indicating a diminished protective effect of gender against ASD symptoms, akin to other syndromic causes of ASD. ^[55]

ADHD in NF-1

Children with NF-1 may experience behavioral difficulties related to inattention, impulsivity, hyperactivity, and inflexibility. ^[56] Studies have shown that clinical criteria for diagnosing ADHD are met by 23% to 50% of children with NF-1. ^[59] Children with NF-1 may sometimes have attention difficulties without hyperactivity or behavioral problems. In such cases, attention deficits might go unnoticed without formal cognitive testing, although some children may have attention issues that, while not severe enough for an ADHD diagnosis, would still benefit from support. ^[56]

Individuals with neurofibromatosis type 1 often exhibit certain brain abnormalities known as T2 hyperintensities (visible on MRI scans), referred to as Unidentified Bright Objects (UBOs), which are located in specific brain regions such as the cerebellum, brainstem, thalamus, and basal ganglia—areas involved in motor signal processing and cognitive functions. ^[59] Some of these brain regions are also connected to attention-related networks, particularly those involved in cognitive flexibility and motor inhibition, which are essential for attention and behavior. It is well established that these networks are impaired in ADHD. ^[59]

Studies suggest that while ADHD symptoms may partially explain attention problems in NF-1, such as impulsivity, they do not fully account for other deficits like cognitive control. ^[59] Children with NF-1 often exhibit impairments in planning, spatial working memory, and response inhibition, independent of ADHD, suggesting that the impact of ADHD on their attention and executive functioning is limited. ^[59]

Although ADHD prevalence is a key factor in NF-1 cognition studies, comparisons between children with NF-1 and ADHD and those without ADHD have not consistently shown clear differences. ^[59] This creates confusion regarding how to differentiate the effects of NF-1 and ADHD on cognition. Moreover, focusing on ADHD symptoms might obscure attention issues that are specifically associated with NF-1. ^[59]

Results from tasks assigned in studies comparing NF-1 + ADHD groups with children who have only ADHD suggest that NF-1 + ADHD is not simply a combination of both conditions, nor does ADHD merely exacerbate attention problems in NF-1. ^[59] These differences are qualitative rather than quantitative, supporting the idea that some deficits are unique to NF-1 and independent of ADHD. Additionally, certain attention issues, such as intrinsic alertness and visual scanning among distractors, may be considered characteristic traits of NF-1. ^[59]

Treatment

Treatment for NF1 is limited, and there is currently no cure. Pain meds can be prescribed to help with pain. In some cases, growths may be removed surgically or reduced with radiation therapy. Treatment options are limited, given the tumours tendency to regrow following surgery and their propensity to transform into malignant tumours following radiation. ^[60] Although surgery in these areas can cause further injury to nerves and additional neurological problems. The benefits of surgery should always be considered against its risks. Some NF tumours are inoperable.

Drug Therapies

Selumetinib

Selumetinib, is a drug produced by Astra Zeneca sold under the brand name Koselugo, and was approved by the FDA in April 2020 ^[61] for the treatment of NF-1 in the pediatric population who are two or more years of age. It is a mitogen-activated protein kinase inhibitor (MEKi) and is indicated for use in pediatric patients who are symptomatic and have inoperable plexiform neurofibromas. ^[62] However, this medication is not curative and is not suitable for all patients.

Side effects of Selumetinib include headache, nausea/vomiting, abdominal pain and other problems of the gastrointestinal tract, fatigue, muscle pain, Constipation, Paronychia as well as dry skin and other skin and hair problems. ^[63] The side effects can have a significant impact on a patient's life and may lead to someone having to discontinue treatment.

In an open-label, phase 2 trial of selumetinib with 50 children:

• 35 patients (70%) had a confirmed partial response, 28 of these patients had a durable response (lasting ≥1 year)
• After 1 year of treatment, the mean decrease in child-reported tumour pain-intensity scores was 2 points, which is considered a clinically meaningful improvement

Prognosis

NF-1 is a progressive and diverse condition, making the prognosis difficult to predict. The NF-1 gene mutations manifest the disorder differently even amongst people of the same family. This phenomenon is called variable expressivity. For example, some individuals have almost no symptoms, while others may have a manifestation that is rapidly more progressive and can lead to significant disability and death.

For many NF-1 patients, a primary concern is the disfigurement caused by cutaneous/dermal neurofibromas, pigmented lesions, and the occasional limb abnormalities. However, there are many more severe complications caused by NF-1 like increased cancer risk, a plexiform neurofibroma has a 10-15% chance of developing into a MPNST (Malignant Peripheral Nerve Sheath Tumour) Epidemiology NF-1 is estimated to affect around 25,000 people in the UK. ^[64]

In popular culture

Victor Hugo's novel The Hunchback of Notre-Dame (1831) is often cited as having influenced popular culture and shaped misunderstandings about neurofibromatosis, as it was assumed that the man who inspired the book's protagonist had neurofibromatosis. ^[65]

For many years, it was thought that Joseph Merrick (popularly known as the Elephant Man) had neurofibromatosis. In 1986, geneticists Tibbles and Cohen theorized that Merrick instead had the much rarer Proteus syndrome. ^[66]

In Abraham Verghese's novel The Covenant of Water (2023), neurofibromatosis is referred to solely as "the condition" and is a key plot point.

In Aaron Schimberg's film A Different Man (2024), the main characters played by Sebastian Stan and Adam Pearson both have neurofibromatosis, which Pearson also has in real life.

See also

• Neurofibromatosis type II
• Characteristics of syndromic ASD conditions

References

1. - Source for main symptoms: "Neurofibromatosis". Mayo Clinic. 2021-01-21.
   - Image by Mikael Häggström, MD, using source images by various authors.
2. Kunc V, Venkatramani H, Sabapathy SR (May 2019). "Neurofibromatosis 1 Diagnosed in Mother Only after a Follow-up of Her Daughter". Indian Journal of Plastic Surgery. 52 (2): 260. doi: 10.1055/s-0039-1693503 . PMC   6785427 . PMID   31602150.
3. "About Neurofibromatosis – The University of Chicago Medicine". www.uchospitals.edu. Archived from the original on 2015-09-07. Retrieved 2015-10-27.
4. Costa RM, Silva AJ (August 2002). "Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1". Journal of Child Neurology. 17 (8): 622–626, discussion 626–9, 626–51. doi:10.1177/088307380201700813. PMID   12403561. S2CID   20385802.
5. "NF1 | Children's Tumor Foundation".
6. Graphical abstract from: Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. (August 2021). "Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation". Genetics in Medicine. 23 (8): 1506–1513. doi:10.1038/s41436-021-01170-5. PMC   8354850 . PMID   34012067.
   - "User License: Creative Commons Attribution (CC BY 4.0)"
7. Viskochil D (2010). "Neurofibromatosis 1: Current Issues in Diagnosis, Therapy, and Patient Management" (PDF). Mountain States Genetic Foundation. Denver. Archived from the original (PDF) on 2015-11-06. Retrieved 2011-05-15.
8. Klesse L (2010). "Current Therapies for Neurofibromatosis Type 1" (PDF). Mountain States Genetic Foundation. Denver. Archived from the original (PDF) on 2012-03-09. Retrieved 2011-05-15.
9. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (May 2002). "Malignant peripheral nerve sheath tumours in neurofibromatosis 1". Journal of Medical Genetics. 39 (5): 311–314. doi:10.1136/jmg.39.5.311. PMC   1735122 . PMID   12011145.
10. Mutua V, Mong'are N, Bundi B, von Csefalvay C, Oriko D, Kitunguu P (September 2021). "Sudden bilateral lower limb paralysis with dural ectasia in Neurofibromatosis type 1: A case report". Medicine: Case Reports and Study Protocols. 2 (9): e0165. doi: 10.1097/MD9.0000000000000165 . ISSN   2691-3895.
11. Summers MA, Quinlan KG, Payne JM, Little DG, North KN, Schindeler A (June 2015). "Skeletal muscle and motor deficits in Neurofibromatosis Type 1". Journal of Musculoskeletal & Neuronal Interactions. 15 (2): 161–170. PMC   5133719 . PMID   26032208.
12. Cornett KM, North KN, Rose KJ, Burns J (August 2015). "Muscle weakness in children with neurofibromatosis type 1". Developmental Medicine and Child Neurology. 57 (8): 733–736. doi: 10.1111/dmcn.12777 . PMID   25913846. S2CID   38835893.
13. Sullivan K, El-Hoss J, Quinlan KG, Deo N, Garton F, Seto JT, et al. (March 2014). "NF1 is a critical regulator of muscle development and metabolism". Human Molecular Genetics. 23 (5): 1250–1259. doi:10.1093/hmg/ddt515. PMC   3954124 . PMID   24163128.
14. Stevenson DA, Allen S, Tidyman WE, Carey JC, Viskochil DH, Stevens A, et al. (September 2012). "Peripheral muscle weakness in RASopathies". Muscle & Nerve. 46 (3): 394–399. doi:10.1002/mus.23324. PMID   22907230. S2CID   21120799.
15. Lakshmanan A, Bubna A, Sankarasubramaniam A, Veeraraghavan M, Rangarajan S, Sundaram M (2016). "A clinical study of neurofibromatosis-1 at a tertiary health care centre in south India". Pigment International. 3 (2): 102. doi: 10.4103/2349-5847.196302 .
16. "Northwestern Health Sciences University ~ Diagnosis and Discussion". www.nwhealth.edu. Archived from the original on 2016-03-04. Retrieved 2015-10-27.
17. Piersall, Linda, David H. Gutmann, & Rosalie Ferner. Living with Neurofibromatosis Type 1: A Guide for Adults. New York, NY: The National Neurofibromatosis Foundation, Inc. Print.
18. MedlinePlus Encyclopedia : Optic glioma
19. Hyman SL, Shores A, North KN (October 2005). "The nature and frequency of cognitive deficits in children with neurofibromatosis type 1". Neurology. 65 (7): 1037–1044. doi:10.1212/01.wnl.0000179303.72345.ce. PMID   16217056. S2CID   10198510.
20. Hyman SL, Gill DS, Shores EA, Steinberg A, Joy P, Gibikote SV, et al. (April 2003). "Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1". Neurology. 60 (7): 1139–1145. doi:10.1212/01.WNL.0000055090.78351.C1. PMID   12682321. S2CID   26812237.
21. Garg S, Lehtonen A, Huson SM, Emsley R, Trump D, Evans DG, et al. (February 2013). "Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study". Developmental Medicine and Child Neurology. 55 (2): 139–145. doi: 10.1111/dmcn.12043 . PMID   23163236. S2CID   11781870.
22. Thompson HL, Viskochil DH, Stevenson DA, Chapman KL (February 2010). "Speech-language characteristics of children with neurofibromatosis type 1". American Journal of Medical Genetics. Part A. 152A (2): 284–290. doi:10.1002/ajmg.a.33235. PMID   20101681. S2CID   26650152.
23. van der Vaart T, van Woerden GM, Elgersma Y, de Zeeuw CI, Schonewille M (June 2011). "Motor deficits in neurofibromatosis type 1 mice: the role of the cerebellum". Genes, Brain and Behavior. 10 (4): 404–409. doi: 10.1111/j.1601-183X.2011.00685.x . PMID   21352477. S2CID   19609654.
24. Vivarelli R, Grosso S, Calabrese F, Farnetani M, Di Bartolo R, Morgese G, et al. (May 2003). "Epilepsy in neurofibromatosis 1". Journal of Child Neurology. 18 (5): 338–342. doi:10.1177/08830738030180050501. PMID   12822818. S2CID   39229702.
25. Listernick R, Charrow J, Gutmann DH (March 1999). "Intracranial gliomas in neurofibromatosis type 1". American Journal of Medical Genetics. 89 (1): 38–44. doi:10.1002/(sici)1096-8628(19990326)89:1<38::aid-ajmg8>3.0.co;2-m. PMID   10469435.
26. Polster SP, Dougherty MC, Zeineddine HA, Lyne SB, Smith HL, MacKenzie C, et al. (May 2020). "Dural Ectasia in Neurofibromatosis 1: Case Series, Management, and Review". Neurosurgery. 86 (5): 646–655. doi:10.1093/neuros/nyz244. PMID   31350851.
27. Cohen JS, Levy HP, Sloan J, Dariotis J, Biesecker BB (November 2015). "Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life". Clinical Genetics. 88 (5): 425–430. doi:10.1111/cge.12551. PMC   4573679 . PMID   25534182.
28. Berardelli I, Maraone A, Belvisi D, Pasquini M, Giustini S, Miraglia E, et al. (November 2021). "The importance of suicide risk assessment in patients affected by neurofibromatosis". International Journal of Psychiatry in Clinical Practice. 25 (4): 350–355. doi:10.1080/13651501.2021.1921217. PMID   34270353. S2CID   235999769.
29. Brar KS, Trivedi C, Kaur N, Adnan M, Patel H, Beg U, et al. (October 2023). "Prevalence of Psychiatric Comorbidities in Patients With Neurofibromatosis". The Primary Care Companion for CNS Disorders. 25 (5): 49254. doi:10.4088/PCC.23m03514. PMID   37816254. S2CID   263240202.
30. Miguel CS, Chaim-Avancini TM, Silva MA, Louzã MR (2015-03-25). "Neurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature review". Neuropsychiatric Disease and Treatment. 11: 815–821. doi: 10.2147/NDT.S75038 . PMC   4378869 . PMID   25848279.
31. Chisholm AK, Haebich KM, Pride NA, Walsh KS, Lami F, Ure A, et al. (January 2022). "Delineating the autistic phenotype in children with neurofibromatosis type 1". Molecular Autism. 13 (1): 3. doi: 10.1186/s13229-021-00481-3 . PMC   8729013 . PMID   34983638.
32. Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, et al. (March 2003). "Growth and pubertal disorders in neurofibromatosis type 1". Journal of Pediatric Endocrinology & Metabolism. 16 (Suppl 2): 289–292. PMID   12729406.
33. Korf BR (March 1999). "Plexiform neurofibromas". American Journal of Medical Genetics. 89 (1): 31–37. doi:10.1002/(sici)1096-8628(19990326)89:1<31::aid-ajmg7>3.0.co;2-w. PMID   10469434.
34. Matsui I, Tanimura M, Kobayashi N, Sawada T, Nagahara N, Akatsuka J (November 1993). "Neurofibromatosis type 1 and childhood cancer". Cancer. 72 (9): 2746–2754. doi: 10.1002/1097-0142(19931101)72:9<2746::AID-CNCR2820720936>3.0.CO;2-W . PMID   8402499.
35. Duong TA, Sbidian E, Valeyrie-Allanore L, Vialette C, Ferkal S, Hadj-Rabia S, et al. (May 2011). "Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France". Orphanet Journal of Rare Diseases. 6: 18. doi: 10.1186/1750-1172-6-18 . PMC   3095535 . PMID   21542925.
36. Suarez-Kelly LP, Yu L, Kline D, Schneider EB, Agnese DM, Carson WE (2019-03-25). "Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature". Hereditary Cancer in Clinical Practice. 17 (1): 12. doi: 10.1186/s13053-019-0110-z . PMC   6434896 . PMID   30962859.
37. "Cancer Statistics Review, 1975-2012". SEER Cancer Statistics Review. Retrieved 2023-11-15.
38. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, et al. (July 1990). "Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients". Science. 249 (4965): 181–186. Bibcode:1990Sci...249..181W. doi:10.1126/science.2134734. PMID   2134734.
39. "neurofibromin 1" GeneCards
40. "Human Gene NF1 (uc002hgf.1) Description and Page Index"
41. Goldberg NS, Collins FS (November 1991). "The hunt for the neurofibromatosis gene". Archives of Dermatology. 127 (11): 1705–1707. doi:10.1001/archderm.1991.01680100105014. PMID   1952978.
42. Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, et al. (June 2010). "NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype". Human Mutation. 31 (6): E1506–E1518. doi: 10.1002/humu.21271 . PMID   20513137. S2CID   24525378.
43. Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, et al. (December 1991). "cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product". Genomics. 11 (4): 931–940. doi:10.1016/0888-7543(91)90017-9. hdl: 2027.42/29018 . PMID   1783401.
44. Gutmann DH, Giovannini M (2002). "Mouse models of neurofibromatosis 1 and 2". Neoplasia. 4 (4): 279–290. doi:10.1038/sj.neo.7900249. PMC   1531708 . PMID   12082543.
45. Feldkamp MM, Angelov L, Guha A (February 1999). "Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway". Surgical Neurology. 51 (2): 211–218. doi:10.1016/S0090-3019(97)00356-X. PMID   10029430.
46. Hannan F, Ho I, Tong JJ, Zhu Y, Nurnberg P, Zhong Y (April 2006). "Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras". Human Molecular Genetics. 15 (7): 1087–1098. doi:10.1093/hmg/ddl023. PMC   1866217 . PMID   16513807.
47. Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, et al. (November 2005). "The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway". The Journal of Biological Chemistry. 280 (47): 39524–39533. doi: 10.1074/jbc.M503707200 . PMID   16169856.
48. Le LQ, Parada LF (July 2007). "Tumor microenvironment and neurofibromatosis type I: connecting the GAPs". Oncogene. 26 (32): 4609–4616. doi:10.1038/sj.onc.1210261. PMC   2760340 . PMID   17297459.
49. Online Mendelian Inheritance in Man (OMIM): NEUROFIBROMATOSIS, TYPE I; NF1 - 162200
50. Blackburn-Starzan A (9 June 2008). "British couple successfully screens out genetic disorder using NHS-funded PGD". BioNews. Archived from the original on March 30, 2016. Retrieved May 16, 2011.
51. "About Neurofibromatosis". Genome.gov. Retrieved 2020-03-05.
52. "Neurofibromatosis: Conference Statement". Archives of Neurology. 45 (5): 575. 1 May 1988. doi:10.1001/archneur.1988.00520290115023.
53. Huson SM, Hughes RA (1994). The neurofibromatoses: a pathogenetic and clinical overview. London: Chapman & Hall. 1.3.2:9. ISBN   978-0-412-38920-7.
54. Rodrigues LO, Batista PB, Goloni-Bertollo EM, de Souza-Costa D, Eliam L, Eliam M, et al. (March 2014). "Neurofibromatoses: part 1 - diagnosis and differential diagnosis". Arquivos de Neuro-Psiquiatria. 72 (3): 241–250. doi: 10.1590/0004-282X20130241 . PMID   24676443.
55. Vogel AC, Gutmann DH, Morris SM (November 2017). "Neurodevelopmental disorders in children with neurofibromatosis type 1". Developmental Medicine & Child Neurology. 59 (11): 1112–1116. doi:10.1111/dmcn.13526. ISSN   0012-1622. PMID   28845518 . Retrieved 2024-10-12.
56. Children’s Tumor Foundation (November 2023). "Learning Disabilities in Children with NF1" (PDF). ctf.org. Retrieved 12 October 2024.
57. Garg S, Plasschaert E, Descheemaeker MJ, Huson S, Borghgraef M, Vogels A, et al. (2015-06-01). "Autism Spectrum Disorder Profile in Neurofibromatosis Type I". Journal of Autism and Developmental Disorders. 45 (6): 1649–1657. doi:10.1007/s10803-014-2321-5. ISSN   1573-3432. PMID   25475362 . Retrieved 2024-07-23.
58. Lubbers K, Stijl EM, Dierckx B, Hagenaar DA, ten Hoopen LW, Legerstee JS, et al. (2022-05-16). "Autism Symptoms in Children and Young Adults With Fragile X Syndrome, Angelman Syndrome, Tuberous Sclerosis Complex, and Neurofibromatosis Type 1: A Cross-Syndrome Comparison". Frontiers in Psychiatry. 13. doi: 10.3389/fpsyt.2022.852208 . ISSN   1664-0640. PMC   9149157 . PMID   35651825.
59. Lion-François L, Herbillon V, Peyric E, Mercier C, Gérard D, Ginhoux T, et al. (November 2020). "Attention and Executive Disorders in Neurofibromatosis 1: Comparison Between NF1 With ADHD Symptomatology (NF-1 + ADHD) and ADHD Per Se". Journal of Attention Disorders. 24 (13): 1807–1823. doi:10.1177/1087054717707579. ISSN   1087-0547. PMID   28587546 . Retrieved 2024-10-24.
60. Coltin H, Perreault S, Larouche V, Black K, Wilson B, Vanan MI, et al. (August 2022). "Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series". Pediatric Blood & Cancer. 69 (8): e29633. doi:10.1002/pbc.29633. PMID   35289492. S2CID   247453317.
61. Office of the Commissioner (2020-04-10). "FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease". FDA. Retrieved 2020-06-21.
62. AstraZeneca Pharmaceuticals LP. Koselugo(Selumetinib)[package insert]. U.S. Food and Drug Administration website.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf. Accessed June 21, 2020.
63. "KOSELUGO- selumetinib capsule". DailyMed. U.S. National Library of Medicine. Retrieved 2023-11-15.
64. Ashton R, Crawford H, Morrison P, McKee S, Huson S (2012). "Neurofibromatosis Type 1 (NF1) a Guide for Adults and Families" (PDF). Nerve Tumours UK. Retrieved 2021-04-27.
65. Valeyrie-Allanore L, Roujeau JC, Revuz J (2005). "Neurofibromatosis type 1: From diagnosis to therapeutic challenges". American Journal of Medical Genetics Part A. 137A (1): 12–23. doi:10.1002/ajmg.a.38486. PMID   29388340.
66. Legendre CM, Charpentier-Côté C, Drouin R, Bouffard C (2011-01-01). "Neurofibromatosis type 1: persisting misidentification of the "elephant man" disease". Journal of the American Board of Family Medicine. 24 (1): 112–114. doi: 10.3122/jabfm.2011.01.100219 . PMID   21209351.